iTeos Therapeutics (NASDAQ:ITOS) Rating Reiterated by HC Wainwright

HC Wainwright reissued their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note published on Monday morning, Benzinga reports. They currently have a $46.00 price objective on the stock.

ITOS has been the subject of a number of other reports. JPMorgan Chase & Co. lowered their target price on shares of iTeos Therapeutics from $27.00 to $24.00 and set an overweight rating for the company in a report on Monday, August 12th. Wells Fargo & Company assumed coverage on iTeos Therapeutics in a report on Tuesday, August 13th. They set an overweight rating and a $31.00 price objective for the company. Finally, Wedbush reaffirmed an outperform rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research report on Thursday, August 8th.

iTeos Therapeutics Stock Performance

ITOS stock opened at $11.22 on Monday. The company has a 50 day moving average price of $16.12 and a two-hundred day moving average price of $14.63. The stock has a market capitalization of $405.30 million, a P/E ratio of -2.97 and a beta of 1.39. iTeos Therapeutics has a one year low of $8.20 and a one year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.86. The business had revenue of $35.00 million during the quarter, compared to analysts’ expectations of $4.20 million. Research analysts forecast that iTeos Therapeutics will post -4.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On iTeos Therapeutics

Several large investors have recently made changes to their positions in the business. Russell Investments Group Ltd. boosted its position in iTeos Therapeutics by 66.3% during the 4th quarter. Russell Investments Group Ltd. now owns 39,508 shares of the company’s stock worth $433,000 after purchasing an additional 15,757 shares during the period. Jump Financial LLC acquired a new stake in shares of iTeos Therapeutics in the fourth quarter valued at about $636,000. Dynamic Technology Lab Private Ltd raised its holdings in shares of iTeos Therapeutics by 357.2% during the 4th quarter. Dynamic Technology Lab Private Ltd now owns 47,461 shares of the company’s stock valued at $520,000 after buying an additional 37,080 shares during the period. Trexquant Investment LP lifted its position in iTeos Therapeutics by 83.8% during the 4th quarter. Trexquant Investment LP now owns 61,658 shares of the company’s stock worth $675,000 after acquiring an additional 28,109 shares in the last quarter. Finally, Quest Partners LLC purchased a new position in iTeos Therapeutics in the 4th quarter worth approximately $90,000. Institutional investors and hedge funds own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.